Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(10):780-781; doi:10.1093/jnci/92.10.780
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sporn, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sporn, M. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 10, 780-781, May 17, 2000
© 2000 Oxford University Press

EDITORIALS

Retinoids and Demethylating Agents— Looking for Partners

Michael B. Sporn

Correspondence to: Michael B. Sporn, M.D., Department of Pharmacology, Dartmouth Medical School, Hanover, NH 03755 (e-mail:Michael.Sporn@Dartmouth.edu).

The concept that carcinogenesis may be the result of a deficiency or a failure of the action of substances that are negative regulators of control of proliferation and growth of cells is hardly new (1) and certainly antedates current interest in the mutation of tumor suppressor genes in the causation of cancer. Thus, in their classic article on the role of retinoid deficiency in control of epithelial proliferation and differentiation, Wolbach and Howe (2) noted that retinoid-deficient epithelial tissues had a premalignant phenotype that was characterized by enhanced mitotic activity and loss of differentiation. Retinoids may indeed be considered prototypes of . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
E. M. Youssef, X.-q. Chen, E. Higuchi, Y. Kondo, G. Garcia-Manero, R. Lotan, and J.-P. J. Issa
Hypermethylation and Silencing of the Putative Tumor Suppressor Tazarotene-Induced Gene 1 in Human Cancers
Cancer Res., April 1, 2004; 64(7): 2411 - 2417.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. M. Youssef, D. Lotan, J.-P. Issa, K. Wakasa, Y.-H. Fan, L. Mao, K. Hassan, L. Feng, J. J. Lee, S. M. Lippman, et al.
Hypermethylation of the Retinoic Acid Receptor-{beta}2 Gene in Head and Neck Carcinogenesis
Clin. Cancer Res., March 1, 2004; 10(5): 1733 - 1742.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. K. Virmani, A. Rathi, S. Zochbauer-Muller, N. Sacchi, Y. Fukuyama, D. Bryant, A. Maitra, S. Heda, K. M. Fong, F. Thunnissen, et al.
Promoter Methylation and Silencing of the Retinoic Acid Receptor-{beta} Gene in Lung Carcinomas
J Natl Cancer Inst, August 16, 2000; 92(16): 1303 - 1307.
[Abstract] [Full Text] [PDF]